NCT04366024

Brief Summary

Investigators use clinical data from a large sample of COVID-19 disease patients to screen out biomarkers associated with disease severity. Then, a novel nomogram model will be established to predict covid-19 disease severity, which could provide important assistance and supplement for clinical work. In the case of extremely shortage of front-line medical resources, patients with potential severe diseases will be timely treated with the help of the novel nomogram model.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 17, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 28, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2020

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

February 23, 2024

Status Verified

February 1, 2024

Enrollment Period

8 months

First QC Date

April 21, 2020

Last Update Submit

February 22, 2024

Conditions

COVID-19 DiseaseNomogram Model

Outcome Measures

Primary Outcomes (2)

  • the consistency of predicted severe rate and observed severe rate of COVID-19 patients

    We aim to use the clinical data of COVID-19 patients to construct a nomogram model to predict the severe rate of each patient, then the the consistency of predicted severe rate and observed severe rate will be evaluated by calibration plot.

    up to 3 months

  • Duration of severe illness

    the duration of severe illness of each patient will evaluated

    up to 3 months

Study Arms (1)

Observed group

COVID-19 disease patients who were detected by RT-PCR and CT imaging.

Other: other

Interventions

otherOTHER

clinical diagnosis

Observed group

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

COVID-19 disease patients

You may qualify if:

  • COVID-19 disease patients confirmed by virus nucleic acid RT-PCR and CT

You may not qualify if:

  • unconfirmed suspected cases
  • Patients during pregnancy and lactation
  • incomplete clinical data
  • investigators considered patients ineligible for the trial
  • Child patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xinqiao Hospital of Chongqing

Chongqing, Chongqing Municipality, 400000, China

Location

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy Director,Head of Oncology department, Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

April 21, 2020

First Posted

April 28, 2020

Study Start

January 17, 2020

Primary Completion

August 30, 2020

Study Completion

December 31, 2021

Last Updated

February 23, 2024

Record last verified: 2024-02

Locations

CN(1)